Back to Search
MARK HUBERMAN, MD
MD
Medical Oncology Physician
NPI: 1477583441Individual
Specialties, Licenses & Credentials
Research & Publications (18)
Subdivision of the T1 size descriptor for stage I non-small cell lung cancer has prognostic value: a single institution experience.
PMID 19525360·Chest·2009
8-other
Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.
PMID 18981003·Clin Cancer Res·2008
8-other
A phase II study of oxaliplatin, pemetrexed, and bevacizumab in previously treated advanced non-small cell lung cancer.
PMID 18827612·J Thorac Oncol·2008
3-trial
BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.
PMID 17973572·PLoS Med·2007
4-observational
Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers.
PMID 17610986·Lung Cancer·2007
8-other
Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial.
PMID 17149608·Cancer Chemother Pharmacol·2007
3-trial
Phase II trial of sequential chemotherapy followed by chemoradiation, surgery, and postoperative chemotherapy for the treatment of stage IIIA/IIIB non-small-cell lung cancer.
PMID 17026813·Clin Lung Cancer·2006
3-trial
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.
PMID 16818686·Clin Cancer Res·2006
8-other
Improvement of type 2 diabetes in a lung cancer patient treated with Erlotinib.
PMID 16801611·Diabetes Care·2006
5-case
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 44 GRAFTON ST
NEWTON, MA 02459 - Phone
- (617) 610-4097
Quick Facts
- NPI
- 1477583441
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 18
Are you this provider?
Claim Your Profile